In reply to Gondi and Mehta.

[1]  M. Mehta,et al.  Dose escalation for GBM in the temozolamide era: in regard to Badiyan et al. , 2015, International journal of radiation oncology, biology, physics.

[2]  E. Leuthardt,et al.  Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide. , 2014, International journal of radiation oncology, biology, physics.

[3]  Christopher U. Jones,et al.  Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. , 2014, International journal of radiation oncology, biology, physics.

[4]  Lawrence Kleinberg,et al.  The Etiology of Treatment-related Lymphopenia in Patients with Malignant Gliomas: Modeling Radiation Dose to Circulating Lymphocytes Explains Clinical Observations and Suggests Methods of Modifying the Impact of Radiation on Immune Cells , 2013, Cancer investigation.

[5]  S. Piantadosi,et al.  Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide , 2011, Clinical Cancer Research.

[6]  J. Fowler,et al.  Correlation of currently used radiobiological parameters with local control and acute and late mucosal toxicity in randomised studies of altered fractionation for locally advanced head and neck cancer. , 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

[7]  A. Niemierko,et al.  A Comparison of Critical Structure Dose and Toxicity Risks in Patients with Low Grade Gliomas Treated with IMRT versus Proton Radiation Therapy , 2009, Technology in cancer research & treatment.

[8]  S. Grossman,et al.  Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. , 2005, International journal of radiation oncology, biology, physics.